Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry

Everolimus is an oral mTOR kinase inhibitor approved for the treatment of patients with metastatic renal cell carcinoma (mRCC) progressing during or after treatment with vascular endothelial growth factor (VEGF)-targeted agents. Using the national RENIS clinical registry, we have retrospectively ana...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Klinická onkologie 2011, Vol.24 (5), p.389-392
Hauptverfasser:	Büchler, T, Dusek, L, Fínek, J, Poprach, A, Budnáková, D, Kandrnal, V, Jarkovský, J, Bortlícek, Z, Klimes, D, Abrahámová, J, Vyzula, R
Format:	Artikel
Sprache:	cze
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - secondary Disease-Free Survival Everolimus Female Humans Kidney Neoplasms - pathology Male Middle Aged Protein Kinase Inhibitors - therapeutic use Sirolimus - analogs & derivatives Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!